Research Question

Есть сайт https://peptidecalchub.com/ можешь проанализировать его что там есть и про что он и дать рекомендации сколько языков необходимо сделать для этого направления. Цель найти свою аудиторию и на каких языках она говорит . что бы не делать 10 языков которые займут очень много времени на перевод 120 страниц а сдеать основные несколько где точно есть наши клиенты. Сейчас на сайте есть английский, русский и немецкий языки. Какое еще минимально необходимое количество языков необходимо добавить ?

Three research lenses point to three different languages

Competitor analysis says ES (validated by cellgenic, the #1 player). Audience/cultural research says PT-BR (Brazil's GLP-1 patent expires March 2026). But raw keyword demand says Polish—the only language with mature native search intent (1,880 SV) and literally zero competition (KD=0 across every query). The three signals disagree because they measure different things: ES has the biggest addressable market, PT-BR has the biggest cultural tailwind, PL has the easiest SEO win available right now.

Insights

• Sitemap registers only 29 URLs per locale despite all 123 pages being translated for RU and DE. Google likely isn't indexing ~94 pages per language.: Every dollar already spent on RU/DE translation is partially wasted. Any new locale launched on the current Nuxt config will inherit the same blind spot. This is the highest-leverage fix in the entire stack—1-2 hours of dev work to recover hundreds of indexable pages.
• Polish has 1,880 SV across core peptide calculator queries with KD=0 on every term, plus a 3,900+ SV adjacent ecosystem around 'peptyd miedziowy' (GHK-Cu).: This is the only language in the analysis where mature native search demand meets zero competition. sfd.pl drives 1.52M monthly visits with active 2024-2025 BPC-157/TB-500 threads—the audience exists, searches in Polish, and finds nothing. First mover takes the entire SERP.
• Competitor signal and keyword demand point in different directions for ES vs PL. cellgenic (63.7K traffic/mo, #1 in niche) launched /es/ as their first non-EN locale—but Ahrefs shows only ~140 SV combined across Spain + Mexico for Spanish peptide queries.: cellgenic is betting on a market that hasn't materialized in search yet (LATAM biohacking audience consumes EN content and YouTube). ES is a longer-term play that requires content marketing to create demand, not capture it. PL captures demand that already exists.
• peptideregenesis.com gets 50.1% of traffic from Germany and 20.8% from France with zero localization—pure EN content ranking in those markets.: Two reads: (1) DACH and FR audiences will read EN if forced to, so your existing DE version should already be capturing the German signal—worth auditing whether it actually does; (2) FR has demonstrable traffic potential that no competitor has captured, but Ahrefs only shows ~100 SV in French. The discrepancy suggests FR-language users search in English. Localization may be lower ROI than expected.
• Brazil's semaglutide patent expires March 2026, triggering a predicted generics explosion in a market already worth $1B+ (60% of LATAM GLP-1). Half of Brazilian peptide searches happen in PT-BR, half in English.: PT-BR has a real time-bound window: launching before March 2026 positions you for a demand spike on dosage calculators. But the 650 SV is split with EN, so you're effectively targeting ~325 SV of incremental PT-only searchers. The case is narrative (the patent cliff) more than current search volume.
• Cost to add one language at AI+light-edit quality is ~$4-8K for full coverage (153,700 words), or ~$500-1,500 for a Tier 1 MVP (calculators + navigation + top-10 peptide profiles).: The economics support launching 2-3 languages this year. The MVP-tier path lets you validate demand per language with $500 commitments before going deep on guides. Critically, image translation is zero—all tables are HTML, no text-in-image work needed.
• Australia's TGA banned BPC-157 in June 2024 (Schedule 4 + Appendix D). Australia currently sends 6.5% of cellgenic's traffic and 5.5% of primepeptides' traffic.: EN traffic from Australia will decline structurally over the next 12-24 months across the entire niche. This isn't a problem to fix—it's context for forecasting. Don't model EN growth assuming AU stays flat.
• Nuxt i18n architecture is already configured correctly: subfolder URLs, complete hreflang sets, locale-specific canonicals. Adding a new language is config + content, not engineering.: The infrastructure decision has already been made well. Time-to-launch for a new locale is bottlenecked by translation quality and the sitemap bug—not by code.

Recommended Actions

1. Fix the Nuxt sitemap config to emit all 123 routes per locale before launching any new language

   RU and DE sitemaps currently register only 29 of 123 translated pages each—~94 pages per language are translated, live, hreflang-correct, but invisible to Google. Launching ES/PL/PT-BR on top of this bug means the new locale loses the same ~76% of its SEO surface area on day one.

2. Launch Polish (PL) as the next locale, starting with Tier 1 MVP + top-10 peptide profiles

   Polish is the only language where mature native demand (1,880 SV across BPC-157, ipamorelin, TB-500, GHK-Cu queries) meets KD=0 across the board. sfd.pl gives you a 1.52M/mo audience already searching in Polish for what PeptideCalcHub builds. No competitor—including wolvestack—has Polish coverage. The adjacent 'peptyd miedziowy' ecosystem (3,900+ SV) maps directly to your GHK-Cu calculator.

3. Launch Portuguese (PT-BR) before March 2026 to ride the semaglutide generics wave

   Brazil's semaglutide patent expires March 2026 in a $1B+ GLP-1 market growing to $3.19B by 2033. PT-BR has 650 SV today with high commercial intent ($150 CPC on peptide calculator), zero localized competitors, and an active forum culture (hipertrofia.org with 15-year peptide threads). The case is timing, not current volume—you want the calculator pages already indexed when the generic spike hits.

4. Defer Spanish (ES) despite the cellgenic signal—or launch it small as a hedge

   cellgenic's /es/ investment is the strongest market signal in the competitor data, but Ahrefs shows only ~140 SV across Spain + Mexico for Spanish peptide queries. The Latin American biohacking audience currently consumes EN content and YouTube. cellgenic is creating demand via content marketing; you'd be paying to create demand too, not capturing existing search intent. If you do launch ES, treat it as a brand/content play with a 12-month payback expectation, not an SEO quick win.

5. Add hreflang='en-NL' and verify EN ranking in google.nl instead of building a Dutch locale

   600 of 820 Dutch-market SV is searches for 'peptide calculator' in English. Building /nl/ pays for a translation that the audience won't search for. The right move is making sure your existing EN content is properly geo-signaled to Dutch users—same logic applies to JP, KR, TR which all search peptide terms in English.

Reports